ContactDictionary

Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Rhabdomyosarcoma, child
Stage/Subtype:  recurrent childhood rhabdomyosarcoma
Trial Type:  Treatment
Results 1-25 of 26 for your search:
Start Over
Vorinostat and Etoposide in Treating Younger Patients With Refractory or Relapsed Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: 10-096, NCI-2011-00493, NCT01294670
To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 months to 21 years
Trial IDs: ABI-007-PST-001, NCI-2015-00737, NCT01962103
Nivolumab with or without Ipilimumab in Treating Younger Patients with Recurrent or Refractory Solid Tumors or Sarcomas
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 30 years
Trial IDs: ADVL1412, NCI-2014-01222, NCT02304458
Pexidartinib in Treating Younger Patients with Refractory Leukemias or Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 30
Trial IDs: 15-C-0093, NCI-2015-00457, 150093, P141640, NCT02390752
Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 to 30
Trial IDs: GO29665, NCI-2016-00541, 2014-004685-25, NCT02639546
Gemcitabine Hydrochloride with or without Pazopanib Hydrochloride in Treating Patients with Refractory Soft Tissue Sarcoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 15 and over
Trial IDs: 7943, NCI-2012-00052, NCT01532687
Donor Bone Marrow Transplant in Treating Patients with High-Risk Solid Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 0 to 40
Trial IDs: J12106, NCI-2013-00702, CIR00008429, CIR00009228, NA_00076243, NCT01804634
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 18
Trial IDs: 116731, NCI-2015-00058, NCT01956669
In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®
Status: Active
Phase: Phase II
Type: Treatment
Age: 14 and over
Trial IDs: ONC2014-001, NCI-2016-01295, 1R44CA183075-01A1, NCT02423863
T-cell Depleted Stem Cell Boost in Improving Graft Function in Patients Who Have Undergone Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 14-228, NCI-2015-00179, NCT02350777
Sirolimus and Metronomic Chemotherapy in Treating Younger Patients with Recurrent and/or Refractory Solid or Central Nervous System Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 30 years
Trial IDs: AFLACST1502, NCI-2015-01637, IRB00082488, NCT02574728
Cabozantinib-S-Malate in Treating Younger Patients with Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 2 to 30
Trial IDs: ADVL1622, NCI-2016-01258, NCT02867592
Efficacy and Safety of LFG316 in Transplant Associated Microangiopathy (TAM) Patients
Status: Active
Phase: Phase II
Type: Treatment
Age: 2 and over
Trial IDs: CLFG316X2202, NCI-2016-01390, NCT02763644
Nab-Paclitaxel and Gemcitabine Hydrochloride in Treating Teenagers or Young Adults with Recurrent or Refractory Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, or Soft Tissue Sarcoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 12 to 30
Trial IDs: MCC-18613, NCI-2016-01837, NCT02945800
Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 12 months to 21 years
Trial IDs: APEC1621SC, NCI-2017-01251, NCT03155620
Iodine I 131 Monoclonal Antibody 8H9 in Treating Patients with Recurrent or Refractory Tumors in the Brain and/or Spinal Cord
Status: Active
Phase: Phase I
Type: Treatment
Age: Any age
Trial IDs: 03-133, NCI-2016-00928, MSKCC-03133, NCT00089245
Donor Hematopoietic Stem Cell Transplant in Treating Young Patients with Relapsed or Refractory Solid Tumors or Lymphomas
Status: Active
Phase: Phase I
Type: Treatment
Age: 2 to 21
Trial IDs: RADIANT, NCI-2012-00588, NCT01625351
Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 17
Trial IDs: CLDK378X2103, NCI-2013-00903, 2012-002074-31, NCT01742286
Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 20 years
Trial IDs: SPOC-2012-001, NCI-2014-02681, NCT02013336
T Cell Receptor Gene Therapy in Treating Younger Patients with Solid Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 35 and under
Trial IDs: 14-C-0059, NCI-2014-02506, P131369, NCT02107963
Donor Natural Killer Cell Infusion after Autologous CD133+ Selected Stem Cell Transplant in Treating Younger Patients with High Risk Solid Tumors or Lymphomas
Status: Active
Phase: Phase I
Type: Treatment
Age: 21 and under
Trial IDs: ASCIST, NCI-2014-00275, NCT02130869
Phase I Trial of Afatinib in Pediatric Tumours
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 17
Trial IDs: 1200.120, NCI-2016-00936, 2014-002123-10, NCT02372006
Simvastatin, Topotecan Hydrochloride, and Cyclophosphamide in Treating Younger Patients with Relapsed and/or Refractory Solid and CNS Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 29
Trial IDs: AFLACST1402, NCI-2015-00420, IRB00078790, NCT02390843
Genetically Modified Donor Stem Cell Transplant Followed by Zoledronic Acid in Treating Younger Patients with Relapsed/Refractory Hematologic Malignancies or High Risk Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 7 months to 21 years
Trial IDs: UW13090, NCI-2015-01163, NCT02508038
Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 1 to 30
Trial IDs: CP-MGA271-04, NCI-2017-00584, NCT02982941
Start Over